Trials / Completed

CompletedNCT00506402

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 30 (estimated)

Sponsor: CASI Pharmaceuticals, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

Conditions

Hematological Malignancies
Myelodysplasia
Agnogenic Myeloid Metaplasia

Interventions

Type	Name	Description
DRUG	MKC-1	Capsule, 30 mg and 100 mg, BID, continuous dosing

Timeline

Start date: 2006-11-01
Primary completion: 2009-01-01
Completion: 2009-04-01
First posted: 2007-07-25
Last updated: 2009-05-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00506402. Inclusion in this directory is not an endorsement.